Skip to main content

EDITORIAL article

Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1531464
This article is part of the Research Topic Methods in Experimental Pharmacology 2023 View all 5 articles

Editorial: Methods in Experimental Pharmacology 2023

Provisionally accepted
  • 1 National Institute of Pharmaceutical Education and Research, Kolkata, Kolkata, India
  • 2 School of Medicine, University of California San Diego, La Jolla, California, United States
  • 3 P.V. Narsimha Rao Telangana Veterinary University, Hyderabad, Andhra Pradesh, India

The final, formatted version of the article will be published soon.

    Experimental pharmacology is a branch of medical science that focuses on studying the effects of drugs through controlled laboratory experiments. It involves in vitro (test tube or cell culture), in vivo (animal or human) models, ex vivo (tissues or organs), in silico (computerbased) and genetic/molecular/imaging techniques. Together, these methods enable researchers to understand drug efficacy, safety, and mechanisms before clinical trials. All experiments involving animals must adhere to the 3Rs principle (Replacement, Reduction, Refinement) and require approval from ethical review boards such as the Committee for the Control and Supervision of Experiments on Animals (CCSEA) in India and similar legal organizations upholding the ethical aspects of animal research throughout the world. This research topic aimed to highlight the latest and most innovative experimental techniques and methods used to investigate fundamental pharmacological questions. Various types of papers, such as review articles or opinions on methodologies or applications, including advantages and limitations, were invited with a focus on shedding light on current technologies and up-to-date methods showing promise in helping to advance the field. In this collection, four interesting papers are published, and we will discuss a brief outline of them here.Vitamia and group designed an interesting two-arm, double-blinded, randomized controlled trial enrolling patients with recurrent aphthous stomatitis (RAS) to investigate the efficacy of an α-mangostin hydrogel film with a chitosan alginate base and was compared with a placebo over 7 days. Currently, they are in the process of recruiting participants for the trial. An earlier study has demonstrated that an in vivo investigation of α-mangostin hydrogel films with a chitosan-alginate base for RAS therapy exhibited a favourable healing response, achieving a healing rate of 93% on the seventh day (Milanda et al., 2022). Similarly, hydrogel film dosage form in transdermal delivery offers several advantages, such as extended and targeted active substance release, enhanced bioavailability, improved solubility, cost efficiency and reduced dosing frequency (Yang and Pierstorff, 2012). These promising reports led them to conduct a clinical trial of α-mangostin hydrogel films with a chitosan-alginate base to evaluate the clinical efficacy and safety in treating patients with RAS.The antifungal drug fluconazole is a third-generation triazole drug widely used to treat systemic and superficial fungal infections (Lee et al., 2021). Irrespective of the broad spectrum of activity and good safety profile, it has limited solubility, requires higher oral doses, and has several negative impacts. Topical dosage forms are available in the market; however, they still face challenges due to limited solubility and skin permeation (Gupta et al., 2010). Cheng et al. Herbal preparation of Long Mu Qing Xin Mixture (LMQXM) is one among various traditional methods to treat attention deficit hyperactivity disorder (ADHD), a prevalent neurodevelopmental disorder in children (Chen and Xiao, 2016;Li et al., 2023). Li et al. have scrutinized the potential pharmacological mechanisms by which LMQXM improves behaviour in spontaneously hypertensive rats (SHR/NCrl). They have reported that LMQXM ameliorated hyperactivity and learning and memory deficits of SHR/NCrl rats in addition to upregulated dopamine, norepinephrine, adenylate cyclase and cAMP levels, and the expression of proteins and genes associated with the DRD1/cAMP/PKA-CREB pathway in prefrontal cortex (PFC) and striatum of the rats. This study tentatively suggests that LMQXM may resolve hyperactivity and learning and memory deficits of SHR/NCrl rats by elevating catecholamine neurotransmitters in the PFC and striatum. This elevation of catecholamine neurotransmitters appears to be linked to the activation of the DRD1/cAMP/PKA-CREB signalling pathway, which is expected to yield potentially optimal results at moderate doses.Aging is a complex, naturally occurring process resulting in a deterioration in cellular homeostasis and increased vulnerability to stressors (Santamaria-Garcia et al., 2023). Reports indicate metabolic diseases expedite human aging (Tang et al., 2013) Though this topic has attracted a limited number of papers, experimental pharmacology is an exciting area that provides the scope for drug discovery and evaluation. This process involves preclinical screening before any potential drug candidate proceeds to clinical study. All four papers are very interesting and cover a mixture of four different areas. We believe that this Research Topic has addressed a few critical areas under the category of Experimental Pharmacology, which may inspire the readers for their research.

    Keywords: Experimental pharmacology, animal model, Stomatitis, Attention deficit - hyperactivity disorder (ADHD), Aging

    Received: 20 Nov 2024; Accepted: 07 Jan 2025.

    Copyright: © 2025 Arumugam, Khurana and Bharani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Somasundaram Arumugam, National Institute of Pharmaceutical Education and Research, Kolkata, Kolkata, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.